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Introduction: Silver–Russell syndrome (SRS) is an imprinting disorder primarily caused 
by genetic and epigenetic aberrations on chromosomes 11 and 7. SRS is a rare growth 
retardation disorder often misdiagnosed due to its heterogeneous and non-specific clinical 
features. The Netchine–Harbison clinical scoring system (NH-CSS) is the recommended tool 
for differentiating patients into clinical SRS or unlikely SRS. However, the clinical diagnosis 
is molecularly confirmed only in about 60% of patients, leaving the remaining substantial 
proportion of SRS patients with unknown genetic etiology. 
Materials and Methods: A cohort of 34 Italian patients with SRS or SRS-like features 
scored according to the NH-CSS and without any SRS-associated (epi)genetic alterations 
was analyzed by high-resolution array-based comparative genomic hybridization (CGH) in 
order to identify potentially pathogenic copy number variants (CNVs). 
Results and Discussion: In seven patients, making up 21% of the initial cohort, five 
pathogenic and two potentially pathogenic CNVs were found involving distinct genomic 
regions either previously associated with growth delay conditions (1q24.3-q25.3, 17p13.3, 
17q22, and 22q11.2-q11.22) and with SRS spectrum (7p12.1 and 7p15.3-p14.3) or 
outlined for the first time (19q13.42), providing a better definition of reported and as yet 
unreported SRS overlapping syndromes. All the variants involve genes with a defined 
role in growth pathways, and for two genes mapping at 7p, IGF2BP3 and GRB10, the 
association with SRS turns out to be reinforced. The deleterious effect of the two potentially 
pathogenic variants, comprising GRB10 and ZNF331 genes, was explored by targeted 
approaches, though further studies are needed to validate their pathogenic role in the 
SRS etiology. In conclusion, we reconfirm the utility of performing a genome-wide scan 
to achieve a differential diagnosis in patients with SRS or similar features and to highlight 
novel chromosome alterations associated with SRS and growth retardation disorders.
Keywords: Silver–Russell syndrome, Netchine–Harbison clinical scoring system, array CGH, pathogenic CNVs, 
differential diagnosis
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INTRODUCTION
Silver–Russell syndrome (SRS; Online Mendelian Inheritance 
in Man (OMIM) #180860, also known as Russell–Silver 
syndrome, RSS) is an imprinting disorder with a broad 
clinical and molecular heterogeneity. The clinical diagnosis 
of SRS is difficult, as many of its features are non-specific and 
overlap with those of several other congenital syndromes; 
moreover, the severity of clinical presentation can be highly 
variable (Wakeling et al., 2017). As recommended by the 
recently published first international consensus statement, the 
Netchine–Harbison clinical scoring system (NH-CSS) (Azzi 
et al., 2015) should be applied for SRS diagnosis (Wakeling et al., 
2017). The NH-CSS includes six key features: being born small 
for gestational age (SGA) (birth weight/length ≤ −2 standard 
deviation (SD)), postnatal growth retardation (weight/length ≤ 
−2 SD), relative macrocephaly at birth (head circumference ≥ 
1.5 SD above birth weight and/or length SD), body asymmetry 
(leg length discrepancy ≥ 0.5 cm or <0.5 cm with at least two 
other asymmetrical body parts), feeding difficulties and/or 
low body mass index (BMI) (BMI ≤ −2 SD at 24 months or 
current use of a feeding tube or cyproheptadine for appetite 
stimulation), and a protruding forehead (Azzi et al., 2015). 
A patient receives a diagnosis of SRS when he/she meets four 
or more of these six criteria (positive NH-CSS ≥4/6), while 
patients with a negative NH-CSS (<4/6) are generally classified 
as unlikely SRS (Azzi et al., 2015). However, despite the high 
sensitivity of this clinical score, patients scoring 4 or more 
criteria may have negative molecular testing and vice versa 
(Tümer et al., 2018). In accordance with the statement, patients 
meeting NH-CSS criteria including both protruding forehead 
and relative macrocephaly, but normal at all molecular tests, 
receive a diagnosis of clinical SRS. The two primary molecular 
causes of SRS are hypomethylation of the distal imprinting 
control region H19/IGF2:IG-DMR (ICR1) at 11p15.5, identified 
in about 30–60% of patients, and maternal uniparental disomy 
of chromosome 7 (upd(7)mat), detected in about 5–10% of 
patients (Wakeling et al., 2017). In addition chromosome 
14q32.2 imprinting defects, underpinning Temple syndrome 
(TS; OMIM#616222), represent an alternative molecular 
diagnosis to SRS, as numerous molecularly confirmed TS 
patients (70–72.7%) were found to fulfill the NH-CSS criteria 
(Kagami et al., 2017; Geoffron et al., 2018). Further rare genetic 
alterations, that is, point mutations in imprinted genes at 
11p15 or in other disease-causing genes, and non-recurrent 
copy number variants (CNVs) affecting different chromosome 
regions have been detected in a small number of SRS patients 
(Bruce et al., 2010; Lin et al., 2010; Spengler et al., 2012; Fuke 
et al., 2013; Inoue et al., 2017; Meyer et al., 2017; Sachwitz et al., 
2017; Wakeling et al., 2017; Tumer et al., 2018).
However, in a significant proportion of SRS patients (up 
to 30%), the molecular etiology remains unknown, and 
SRS represents primarily a clinical diagnosis. Genome-wide 
approaches such as chromosome microarray analysis and next-
generation sequencing in patients referred for SRS testing have 
been shown to enhance the molecular diagnosis, often unveiling 
SRS overlapping disorders (Bruce et al., 2010; Spengler et al., 2012; 
Fuke et al., 2013; Inoue et al., 2017; Meyer et al., 2017; Sachwitz 
et al., 2017; Tumer et al., 2018). To this purpose, and to identify 
novel rearrangements and genes related to SRS, we performed 
high-resolution array-based comparative genomic hybridization 
(aCGH) analysis on a group of 34 patients, fulfilling and not 
fulfilling the NH-CSS criteria, without a molecular diagnosis.
MATERIAlS AND METHODS
Study Cohort
The study population consisted of 34 Italian patients (19 males 
and 15 females) born SGA and/or with postnatal growth 
retardation referred as SRS for diagnostic testing and found 
negative for H19/IGF2:IG-DMR LOM and upd(7)mat.
Clinical information was collected by clinicians at different 
hospitals who participated in the study, using the same clinical 
datasheet. SRS clinical scoring was based on the NH-CSS (Azzi 
et al., 2015) with exceptions when postnatal growth and BMI were 
assessed at different ages, as performed by Meyer et al. (2017). 
NH-CSS was assessed in all but two patients due to incomplete 
clinical data. Neonatal SD was calculated according to the 
Italian Neonatal Study (INeS) charts (http://www.inescharts.
com/), whereas postnatal SD was assessed according to Cacciari 
et al. (2006). Of the 32 patients, 21(66%) satisfied NH-CSS, 19 
out of 21 with a score ≥4/6 and two with a score ≥4/5 as the 
macrocephaly at birth was missing in the latter. Among the 
patients fulfilling the NH-CSS criteria, 42% (8/19) showed 
both protruding forehead and relative macrocephaly at birth, 
consistent with clinical SRS. The remaining 11 patients turned 
out to have a negative clinical score but were included in the 
study since they presented other clinical features suggestive of 
SRS, for example, triangular face and/or micrognathia and/or 
fifth finger clinodactyly; in detail, seven patients matched three 
NH-CSS criteria, and four presented only two clinical items. 
Furthermore, in all patients with a positive clinical score for SRS, 
aberrant methylation/uniparental disomy of the imprinted locus 
MEG3-DMR in 14q32 was ruled out. Table 1 reports the clinical 
data and the presence/absence of the various NH-CSS criteria 
in our whole SRS cohort and its two clinical subgroups. Table 1 
also provides the frequency of each clinical finding of the scoring 
system in our clinically confirmed SRS subgroup compared 
with that in literature, showing a substantial level of consistency 
between the two cohorts.
The study was approved by the ethical committee of IRCSS 
Istituto Auxologico Italiano, and written informed consent was 
obtained from the parents for publication of the study and any 
accompanying images.
aCGH and CNV Analysis
aCGH analysis was performed using the high-resolution Human 
Genome CGH Microarray Kits, namely, microarray formats 244K 
(median resolution of 27 kb) (18 patients) and 2 × 400K (median 
resolution of 16 kb) (16 patients) (Agilent Technologies, Palo 
Alto, CA) in accordance with the manufacturer’s instructions. 
Data were then extracted and analyzed for copy number changes 
using Agilent CytoGenomics 3.0.
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Detected CNVs, identified by at least three consecutive 
aberrant probes, were compared with the Database of Genomic 
Variants (DGV) (http://projects.tcag.ca/variation/, release 
March 2016), to exclude common copy number polymorphisms 
(frequency >1%). A CNV was classified as rare if unreported or 
reported at a very low frequency («1%) according to the DGV. 
Inherited rare CNVs were considered automatically validated, 
whereas the de novo CNVs (or with an unknown inheritance), 
detected by a number of oligonucleotide consecutive probes 
≤5, were validated using quantitative polymerase chain 
reaction (qPCR).
The establishment of CNV pathogenicity was made considering 
inheritance, familial segregation, and the consultation of public 
databases, to assess (i) whether the CNVs overlap with common 
microdeletion/microduplication syndromes, (ii) the CNVs’ 
gene content, and (iii) the clinical information of patients with 
similar CNVs. Specifically, the following public databases were 
consulted: University of California Santa Cruz (UCSC) (http://
genome.ucsc.edu/, release February 2009), OMIM (www.ncbi.
nlm.nih.gov/OMIM), International Standards for Cytogenomic 
Arrays (ISCA) (https://www.clinicalgenome.org/, update 
November 2012), DECIPHER v9.10 (http://www.sanger.ac.uk/
PostGenomics/decipher/, last access December 2016) (Bragin 
et al., 2014), and PubMed (https://www.ncbi.nlm.nih.gov/
pubmed/, last access March 2016). The involvement of the 
identified genes in cell cycle, developmental process, and/or cell 
growth pathways was investigated using Entrez Gene (https://
www.ncbi.nlm.nih.gov/gene) and potential interaction with 
already-associated SRS genes was assessed with STRING, a tool 
for Protein–Protein Interaction Networks (https://string-db.
org/). Finally, the evaluation of imprinting status of the genes 
involved in the regions was carried out using the Geneimprint 
database (http://www.geneimprint.com/site/genes-by-species), 
and a search for murine knockout phenotypes with growth 
impairment was made with the Mouse Genome Informatics 
(MGI) database (Eppig et al., 2012).
The guidelines suggested by Miller et al. (2010) and 
successively by the American College of Medical Genetics 
(Kearney et al., 2011) were followed for CNV classification with 
minor modifications.
Microsatellite Analysis
To assess the parental origin of the structural variant at 
7p15.3p14.3 identified in patient 20, microsatellite analysis 
was performed using 8 STR markers, that is, D7S513, D7S493, 
D7S673, D7S2525, D7S2449, D7S516, D7S2496, and D7S526, 
within chromosome 7p. All fluorescent PCR amplicons were run 
TABlE 1 | Distribution of our SRS cohort, negative to 11p15 defects and upd(7)mat, according to NH-CSS criteria and comparison with literature.
SRS study cohort 
11p15 lOM and upd(7)
mat excluded
SRS study cohort 
NH-CSS <4 group
SRS study cohort 
NH-CSS ≥ 4 group
Reference SRS cohort 
NH-CSS ≥4,11p15 lOM 
and upd(7)mat excluded 
(Wakeling et al., 2017)
Reference SRS cohort 
11p15 lOM and upd(7)
mat and/or NH-CSS ≥4 
(Wakeling et al., 2017)
Patient no. and (%) 34 # 11 (34%) 21 (66%) – –
Age at examination (years) 4.0 ± 3.7 5.8 ± 4.2 3.0 ± 3.0 – –
NH-CSS factors% and 
(patients no)
Birth weight/height ≤ −2 SD 64% (21/33) 54% (6/11) 71% (15/21) 85.7% (12/14) 91.7% (55/60)
Relative macrocephaly at 
birth §
36% (10/28) 22% (2/9) 42% (8/19) 55.4% (31/56) 85.7% (179/209)
Postnatal growth failure ‡ 91% (30/33) 82% (9/11) 95% (20/21) 86.8%* (72/83) 84.2% * (267/317)
Protruding forehead 80% (25/31) 50% (5/10) 95% (20/21) 77.6% (59/76) 88.1% (177/201)
Body asymmetry 41% (13/32) 9% (1/11) 57% (12/21) 39.5% (62/157) 57.3% (/271473)
Feeding difficulties and/
or BMI ≤ −2 SD
79% (26/33) 54% (6/11) 95% (20/21) 54.8%** (40/73) 70.4% ** (216/307)
Additional signs% and 
(patients no)
Preterm birth 42% (13/31) 55% (5/9) 38% (8/21) n.k.
Triangular face 84% (26/31) 90% (9/10) 80% (16/20) 98.7% (73/74) 93.9% (154/164)
Micrognathia 55% (17/31) 60% (6/10) 50% (10/20) 56% (5/9) 61.7% (71/115)
Downturned mouth 53% (16/30) 30% (3/10) 65% (13/20) 39.1% (9/23) 47.7% (84/176)
low-set and/or 
posteriorly rotated ears
30% (9/30) 40% (4/10) 25% (5/20) 35.9% (28/78) 49.3% (131/266)
Clinodactyly of 5th finger 55% (17/31) 50% (5/10) 57% (12/21) 77.8% (63/81) 74.6% (238/319)
2nd or 3rd toe syndactyly 16% (5/31) 30% (3/10) 9.5% (2/21) 16% (12/75) 29.9% (79/264)
low muscle mass 28% (9/32) 18% (2/11) 33% (7/21) 34.8% (8/23) 56.3% (58/103)
Male genital abnormalities 44% (8/18) 50% (3/6) 41.6% (5/12) 37.5% (3/8) 40% (34/85)
Psychomotor delay 33% (9/27) 45% (5/11) 25% (4/16) 41.3%*** (26/63) 36.6%*** (93/254)
Speech delay 28.5% (6/21) 33% (3/9) 17% (3/12) 38.5% (20/52) 39.7% (75/189)
#Incomplete clinical evaluation in 2 patients; §Head circumference SD ≥1.5 higher than birth weight or length SD;
‡Weight and/or length ≤ −2 SD at the age of evaluation; *Only postnatal height considered **Only feeding difficulties considered, ***Only motor delay considered;  
n.k., not known; SRS, Silver–Russell syndrome; NH-CSS, Netchine– Harbison clinical scoring system.
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on capillary electrophoresis using the 3500 Genetic Analyzer 
(Applied Biosystems). Data analysis and genotyping were carried 
out by the Genemapper software (Applied Biosystems), matching 
parents to proband transmission.
Real-Time Reverse Transcriptase 
(RT)-PCR
Quantitative gene expression analysis was performed in 
patients 18 and 20 to explore a potential dysregulation in gene 
expression mediated by the CNVs identified in the patients. 
Total RNA of patients, their parents, and 10 healthy controls 
were collected using Tempus Blood RNA tubes (Thermo 
Fisher Scientific, Waltham, MA), isolated using the Tempus 
Spin RNA Isolation kit (Thermo Fisher Scientific), and 
reverse transcribed using the High-Capacity cDNA Reverse 
Transcription kit (Thermo Fisher Scientific). Quantitative 
real-time RT-PCR, based on the TaqMan methodology, was 
performed using an ABI PRISM 7700 Sequence Detection 
System (Applied Biosystems, Foster City, CA). In patient 18, 
the amounts of GRB10 mRNA were calculated using the 2−ΔΔCt 
method (Livak and Schmittgen, 2001), with GAPDH, HMBS, 
RPRPL0, and TBP as the endogenous-normalizing genes, while 
in patient 20 the amounts of IGF2BP3 mRNA were calculated 
with the same method, using the GAPDH, GUSB, and TBP as 
the endogenous-normalizing genes. All assays were provided 
by Thermo Fisher Scientific (TaqMan Gene Expression 
Assays: ID# Hs00959293_m1, GRB10; Hs00946580_m1, 
IGF2BP3; Hs99999905_m1, GAPDH; Hs00939627_m1, 
GUSB; Hs00609297_m1, HMBS; Hs99999902_m1, RPLP0; 
and Hs99999910_m1, TBP). Real-time data were analyzed 
using the RQ Manager 1.2 software (Applied Biosystems). 
For each gene of interest, we established the proper range of 
gene expression in 10 healthy controls by calculating the mean 
value ± 2 SD. If the expression level of the CNV carrier was 
out of the control range, a likely dysregulation of the index 
gene mediated by the CNV was inferred.
Quantitative PCR
qPCR analysis was performed on genomic DNA of patients 
8 and 20 using SYBR Green methodology (Thermo Fisher 
Scientific). qPCR was used in patient 8 to finely map the 
proximal CNV boundary at 19q13.42, and in patient 20 to 
validate the presence of a small de novo deletion at 7p21.1 
detected by three aCGH probes. All amplicons were chosen 
within non-repeated portions of the chromosomes using 
Primer3 software (http://bioinfo.ut.ee/primer3-0.4.0/). A 
control amplicon was selected with the same parameters in 
the PCNT gene at 11q14.1. Size (approximately 60–100 bp) 
and Tm (60°C) were the same for all amplicons. Amplification 
and detection were performed on the ABI PRISM 7900HT 
Sequence Detection System (Applied Biosystems); thermal 
cycling conditions were 50°C for 2 min and 95°C for 10 min, 
followed by 40 cycles at 95°C for 15 s and 60°C for 1  min. 
Each experiment was performed in triplicate on patients, 
parents, and two controls. The results were acquired with the 
SDS v2.3 software (Applied Biosystems) and processed using 
RQ Manager 1.2 (Applied Biosystems). Relative quantification 
of the amount of DNA was obtained using the 2−ΔΔCt method 
(Livak and Schmittgen, 2001). The primer pairs used are 
summarized in Supplementary Table 1.
Sequencing Analysis
In patient 28, carrier of a genomic deletion involving the 
TRIM37 gene, causative of the recessive disease MULIBREY 
nanism (OMIM#253250), the entire coding sequence, intron–
exon junctions, and untranslated exons of the TRIM37 
gene (RefSeq Accession: NM_001005207) were amplified 
for mutation screening by PCR using the AmpliTaq Gold® 
kit (Thermo Fisher Scientific). Sequencing was performed 
using the Big Dye® Terminator v.3.1 Cycle Sequencing kit 
(Thermo Fisher Scientific). Sequences were then aligned 
to the human reference genome sequence (human genome 
assembly GRCh37/hg19) and analyzed with the ChromasPro 
1.5 software (Technelysium Pty Ltd., Tewantin QLD, 
Australia). The primer pairs and amplification conditions are 
summarized in Supplementary Table 2.
Pyrosequencing
Pyrosequencing analysis was performed in patients 8 and 18 to 
assess a perturbation in the methylation level, respectively, of 
GRB10 and ZNF331 differentially methylated regions (DMRs), 
possibly mediated by the structural variants identified in the 
patients. Sodium bisulphite conversion of DNA (500–700 ng) 
was performed by the EZ DNA Methylation Kit (Zymo Research 
Corporation, Orange, CA). PCR analysis was performed on 
bisulphite-treated DNA using forward and reverse primers, one 
of which was biotinylated.
Two assays specific for GRB10:alt-TSS-DMR, that 
is, fragment I (chr7:50849713-50850034, hg19) and II 
(chr7:50850569-50850872, hg19), and one assay specific 
for ZNF331:alt-TSS-DMR2 (chr19:54058016-54058229, 
hg19) were designed for patients 8 and 18, respectively. 
Pyrosequencing experiments were performed using specific 
sequencing primers to quantify four CpG sites for ZNF331, 
eight for GRB10 fragment I, and six sites for GRB10 fragment 
II. Quantitative DNA methylation analysis was performed 
using a Pyro Mark ID instrument (QIAGEN, Silicon Valley, 
CA) in the PSQ HS 96 System with the PyroGold SQA reagent 
kit (Diatech Pharmacogenetics srl, Jesi, Italy) according to the 
manufacturer’s instructions. Raw data were analyzed using 
Q-CpG software v1.0.9 (Qiagen srl), which calculates the ratio 
of converted C’s (T’s) to unconverted C’s at each CpG, giving 
the percentage of methylation.
For each sample, the methylation value represents the mean 
between at least two independent PCR and pyrosequencing 
experiments. For each assay, we established the proper 
range of methylation in healthy controls by calculating the 
mean value ± 2 SD; 11 controls for ZNF331, 24 controls for 
GRB10 fragment I, and eight controls for GRB10 fragment II 
were used.
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The primer pairs and amplification conditions are summarized 
in Supplementary Table 3.
RESUlTS
Genomic Imbalances by aCGH and 
Clinical Records of the Carrier Patients
DNA samples from 34 patients with a clinical suspicion of SRS were 
screened by aCGH analysis. In total, in 22 of the 34 patients (65%), 
40 CNVs classified as rare in the Database of Genomic Variants 
were detected. Of the 40 variants, 18 were deletions (ranging from 
11 kb to 11 Mb), and 22 were duplications (ranging from 22.8 kb to 
3 Mb). The aCGH of parental DNA revealed that in four patients, 
the variants were de novo, whereas in 15 patients, they had been 
inherited from an unaffected parent. Parental DNA samples were 
not available in three patients (Supplementary Table 4).
The role of CNVs in SRS-like clinical presentation was assessed 
by integrating the analysis of gene content, with a focus on genes 
involved in growth and development, with literature and database 
information. We categorized as pathogenic five CNVs, including 
four de novo CNVs and one inherited unmasking a recessive 
allele, and as potentially pathogenic (PP) two inherited CNVs 
(Table 2). All the remaining CNVs (n = 33) were considered 
either VOUS, that is, variants of unknown significance, or likely 
benign (LB) CNVs (Supplementary Table 4). All pathogenic and 
PP-CNVs identified in patients were submitted to the ClinVar 
database (http://www.ncbi.nlm.nih.gov/clinvar/, 19 December 
2018, date last accessed; accession numbers SCV000863548 to 
SCV000863554).
Table 3 outlines the NH-CSS on the basis of the main clinical 
features at birth and at last clinical evaluation of the seven 
patients found to carry pathogenic (n = 5) and PP (n = 2) CNVs.
Pathogenic Variants (P-CNVs)
Overall, chromosomal imbalances with obvious pathogenicity 
could be identified in five patients (7, 17, 20, 23, and 28) (Table 2). 
Figure 1 shows the genomic regions containing the pathogenic 
CNVs of the carrier patients.
We identified in patient 7 a de novo deletion of 11 Mb at 
1q, arr[GRCh37] 1q24.3q25.3(172652343_183538289)x1 dn, 
comprising 98 RefSeq genes (Table 2, Figure 1A). Deletions 
within the critical region 1q24q25 (Figure 1A) have been 
associated with a distinctive syndromic phenotype characterized 
by facial dysmorphism, small hands and feet with fifth finger 
clinobrachydactyly, severe proportionate short stature with 
microcephaly, and severe cognitive disability (Burkardt et al., 
2011; Ashraf et al., 2015). Patient 7 was born preterm with 
cesarean section due to severe intrauterine growth restriction 
(IUGR) in the context of altered umbilical arterial flow and 
insufficient placental supply. In the first months of life, he had 
feeding difficulties, requiring gastric tube feeding (Table 3). At 
clinical evaluation at 28 months, he showed growth retardation, 
slight dolichocephaly, triangular face, slight micro-retrognathia, 
and teeth and genital abnormalities (Table 3, Figure 2A). He 
also displayed bilateral fifth finger clino/brachydactyly, flat feet, 
and delayed bone maturation, as revealed by a skeletal survey 
performed at 11 months (Figure 2A). Further medical problems 
included slight global developmental delay, attention deficit, and 
TABlE 2 | Genomic imbalances detected using array CGH and categorized as pathogenic (P) or potentially pathogenic (PP) variants.
Patient# Gain/ 
loss
CNV description according to the ISCN 
nomenclaturea
Size Inheritance No. of 
affected 
genes
DECIPHERb Genes with functions in cell 
cycle, developmental process, 
and cell growth pathways
P-CNV
#7 Loss arr[GRCh37] 
1q24.3q25.3(172652343_183538289)x1 dn
11 Mb De novo 98 13 CENPL, GAS5, TNN, RFWD2, 
PAPPA2, BRINP2, RASAL2, ABL2, 
QSOX1, LHX4, CACNA1E, RGS16, 
LAMC1
#17 Gain arr[GRCh37]  
17p13.3(1130776_1361490)x3 dn
231 kb De novo 5 TUSC5, YWHAE, CRK
#20 Loss arr[GRCh37] 
7p15.3p14.3(23236782_30690453)x1 dn
7.5 Mb De novo 80 5 GPNMB, IGF2BP3, NPY, SKAP2, 
HOXA1, HOXA2, HOXA3, HOXA4, 
HOXA5, HOXA6, HOXA7, HOXA9, 
HOXA10, HOXA11, HOXA13
#23 Loss arr[GRCh37] 
22q11.2q11.22(21808950_22963000)x1 dn
1.15 Mb De novo 21 10 UBE2L3, MAPK1
#28 Loss arr[GRCh37]  
17q22(57075470_57235248)x1 mat
159.8 kb MAT 3 1 TRIM37
PP-CNV
#8 Gain arr[GRCh37]  
19q13.42(54039784_54484439)x 3 mat
445 kb MAT 58 ZNF331
#18 Gain arr[GRCh37]  
7p12.1(50981149_51956510)x 3 mat
975 kb MAT 1 (GRB10)
a International System for Human Cytogenomic Nomenclature (ISCN 2016).
bNumber of reported patients with overlapping CNVs and prenatal and/or postnatal growth retardation.
() genes possibly deregulated by a position effect mechanism.
CGH, comparative genomic hybridization; CNV, copy number variant.
Frontiers in Genetics | www.frontiersin.org October 2019 | Volume 10 | Article 955
aCGH in Unsolved SRS PatientsCrippa et al.
6
reduced social interaction. The small number of clinical features 
reminiscent of SRS is consistent with a clinical score of 3/6 
(Table 3). Based on the partial overlap of the patient’s CNV with 
the 1q24q25 microdeletion syndrome critical region, the gene 
content of this region was taken into account in the re-evaluation 
of the overall patient’s phenotype.
Patient 17 was found to carry a de novo 230-kb 
duplication in 17p13.3 affecting five genes, arr[GRCh37] 
17p13.3(1130776_1361490)x3 dn, mapping inside the region 
causative of the 17p13.3 duplication syndrome (OMIM#613215) 
and the Miller–Dieker syndrome (MDS, OMIM#247200) 
(Table 2, Figure 1B). The patient was born at term with slight 
growth restriction, which worsened in the next months when 
he also presented feeding difficulties (Table 3). His features are 
consistent with clinical SRS diagnosis: he fulfilled four out of six 
criteria and showed typical SRS facial appearance characterized 
by relative macrocephaly, triangular face, prominent forehead, 
and downturned mouth with thin lips. Further medical problems 
included hypotonia and muscular hypotrophy, typical of 17p13.3 
duplication syndrome.
In patient 20, a de novo deletion of 7.5 Mb at 7p was detected, 
arr[GRCh37] 7p15.3p14.3(23236782_30690453)x1 dn, including 
80 RefSeq genes (Table 2, Figure 1C). The patient was born at 
term and showed prenatal as well as postnatal growth restriction 
(Table 3). She had feeding difficulties and motor delay as she sat 
up alone at 9 months and walked autonomously at 17 months. 
Clinical evaluation at 4 years revealed relative macrocephaly, 
triangular face, and prominent forehead (Figure 2B). Her features 
satisfied four NH-CSS criteria; however, clinical SRS diagnosis 
cannot be confirmed, as she did not show relative macrocephaly 
at birth. Neuropsychological evaluation at age 10 using Wechsler 
Intelligence Scale for Children (WISC)-III scales (Wechsler, 
2002) showed borderline intellectual functioning (QIT: 79; QIV: 
78; and QIP: 85), as the girl needed a support teacher at high 
TABlE 3 | Clinical data of patients from the study cohort carrying pathogenic (P) or potentially pathogenic (PP) variants.
Patient P-CNV PP-CNV
7 17 20 23 28 8 18
NH-CS 3/6 4/6 4/6 2/6 5/6 n.d. 4/5
Sex Male Male Female Female Male Female Female
Gestational age 34 38 38+2 35 36 39 32
Birth length(SD) 38 cm (−2.36) 46 cm (−1.76) 43.4 cm (−2.45) 41 cm (−1.99) n.k. (−2) 48 cm (−0.61) 38 cm (−1.51)
Birth weight (SD) 1087 g (−2.51) 2500 g (−1.69) 1925 g (−2.6) 1570 g (−2.01) 2060 g (−1.42) 2940 g (−0.54) 1230 g (−1.36)
OFC at birth (SD) 27 cm (−2.49) 33.5 cm (−0.57) 31.1 cm (−1.89) 29 cm (−2.02) n.k. (−2) n.k. n.k.
Relative 
macrocephalyat birth
No Yes No No No n.k. n.k.
Age at examination 28 months 11 months 6 years 1 month 3 years 3 years 2 months 12 years 7 months 11 years
length (SD) 76 cm (−3.77) 75 cm (0.19) 99.8 cm (−3.16) 85.3 cm (−2.45) 79.6 cm (−3.76) 141.5 cm (−1.95) 130 cm (−2.23)
Weight (SD) 8.7 kg (−4.55) 7.1 kg (−2.56) 12.1 kg (−4.43) 9.8 kg (−3.52) 8.2 kg (−6.3) 36.5 kg (−1.39) 22.5 kg (−2.9)
BMI (SD) 15.3 (−0.88) 12.6 (−3.78) 12.1 (−3.25) 13.47 (−1.84) 12.94 (−3.39) 18.2 (−0.66) 13.3 (−2.7)
Relative macrocephaly No Yes Yes No No n.k. No
Feeding difficulties Yes Yes Yes No Yes n.k. Yes
Protruding forehead No Yes Yes No Yes No Yes
Body asymmetry No No No No Yes n.k. Yes
Craniofacial 
dysmorphisms
Slight dolichocephaly, 
triangular face, 
downturned corners 
of the mouth, 
diastema of maxillary 
central incisors, 
fusion of upper 
right central and 
lateral incisor, slight 
micro-retrognathia
Triangular face, 
downturned 
mouth, thin lips
Triangular face Triangular face, 
downturned 
mouth, thin lips, 
abnormal ears
(Mozzillo et al., 
2016)
Triangular face, thin 
lips, micrognathia
Deep-set eyes, 
prognathism, 
bushy eyebrows
Psychomotor 
developmental delay
Yes, only 
developmental
No Yes No (Mozzillo et al., 
2016)
n.k. Yes
Other findings 5th finger clino/
brachydactyly,flat 
feet, delayed bone 
maturation, balanic 
hypospadias with 
chordae of penis 
and schisis of 
prepuce,attention 
deficit, poor social 
interaction
5th finger clino/
brachydactyly, 
right undescended 
testicle, muscle 
hypotonia
Myopia and 
astigmatism, 
small hands with 
5th finger clino/
brachydactyly, 
small feet with 
short and broad 
halluces and 
symmetric skeletal 
anomalies, duplex 
collecting system 
of right kidney
5th finger clino/
brachydactyly, 
2nd and 3rd toe 
syndactyly
(Mozzillo et al., 
2016)
n.k. Gastroesophageal 
reflux, 
gastrointestinal 
abnormalities
n.k., not known; CNV, copy number variant; OFC, occipitofrontal head circumference; BMI, body mass index.
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school. Her height improved from −3.16 SD (age 6 years) to −1.84 
SD (age 10 years) in response to growth hormone (GH) therapy, 
and bone age assessment at 11 years showed a correspondence 
between bone age and chronological age. She also presented 
features not belonging to the SRS spectrum, such as small hands 
and feet with symmetric skeletal anomalies (Figure 2B), and 
duplex collecting system of the right kidney.
Segregation analysis from parents to proband of D7S493 and 
D7S2525 microsatellites, mapping inside the 7.5-Mb deletion, 
showed that the deletion occurred on the paternal chromosome 
FIGURE 1 | Physical map of the genomic regions containing the pathogenic CNVs identified by array CGH. (A) 1q24.3-q25-5 region showing the deletion detected 
in patient 7. (B) 17p13.3 region showing the duplication detected in patient 17. (C) 7p21.1-p14.3 region showing the deletion detected in patient 20.  
(D) 22q11.21-q11.22 region showing the deletion detected in patient 23 and the low copy repeats (LCR-E and LCR-D) surrounding the deletion bkps. (E) 17q22 
region showing the deletion and the mutation c.1949-12 A > G involving TRIM37 gene detected in patient 28. The RefSeq genes are depicted in dark blue, and 
the OMIM disease genes in green; the disease critical regions are indicated by black bars, the deletions by red bars, the duplications by blue bars, the deletions of 
previously reported SRS patients by red-white bars, and the candidate genes by red boxes. The images are a modification of a version obtained from the UCSC 
Genome Browser (human genome assembly GRCh37/hg19). CNVs, copy number variants; CGH, comparative genomic hybridization; OMIM, Online Mendelian 
Inheritance in Man; SRS, Silver–Russell syndrome; UCSC, University of California Santa Cruz.
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FIGURE 2 | Photographs of patients 7 (A) and 20 (B). (A-1) Face and whole body of patient 7 at 28 months showing proportionate short stature, mild craniofacial 
dysmorphisms, that is, triangular face and slight micrognathia, and flat feet. (A-2 and 3) Left hand and feet X-rays of the patient at 11 months showing (A-2) 
absence of the carpal bone nuclei, suggestive of a delayed bone age, fifth finger clinodactyly with hypoplastic and triangular shaped intermediate phalanx and distal 
phalanx hypoplasia, and (A-3) short first toes. The absence of bone nuclei at the carpus (A-2) and their presence at the tarsus (A-3) suggest a non-uniform pattern 
of skeletal maturation. (B-1, B-2, and B-3) Facial appearance of patient 20 at 4 years (B-1) and 10 years (B-2, B-3) showing prominent forehead and triangular 
face more evident in childhood. (B-4) Small hands with proximal placement and ulnar side bowing of first fingers, and clinodactyly of fifth fingers. (B-5) Left hand 
X-rays of the patient at 10 years showing hypoplasia of distal phalanges. (B-6) Small feet with short and broad halluces, right over-riding toes, and small/deep-set 
nails. (B-7) Feet X-rays of the patient at 4 years showing proximal placement of fifth metatarsals, absence of distal phalanges in second and fifth toes, absence of 
middle phalanges in fifth toes, and phalanges hypoplasia.
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(Supplementary Figure 1). In order to assess whether the 
insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3) 
gene (OMIM*608259)—involved in the deletion and potential 
candidate for the patient’s phenotype—might be downregulated, 
gene expression analysis was performed. Real-time RT-PCR 
analysis confirmed the hypothesis, identifying a halved amount 
of IGF2BP3 transcript in the patient compared with controls 
(Supplementary Figure 1). It is worth noting that patient 20 has 
two further deletions on proximal 7p, the first at 7p21.3 sized 81 
kb and the second at 7p21.1 of 11 kb, both categorized as VOUS.
A de novo deletion of 1.15 Mb at 22q, arr[GRCh37] 
22q11.2q11.22(21808950_22963000)x1 dn, encompassing 
21 RefSeq genes, was identified in patient 23 (Table 2, Figure 
1D). The deletion overlaps the critical region of distal 22q11.2 
microdeletion syndrome (OMIM#611867), which is associated 
with a variable phenotype with prenatal growth delay. The girl 
was born preterm, at 35 weeks of gestation, and showed SGA, a 
triangular face, and fifth finger clinodactyly (Table 3). Growth 
retardation persisted at the age of 3 years. No cardiac defects 
or other features frequently associated with distal 22q11.2 
microdeletion were present. The molecular findings did not 
confirm the initial clinical suspicion of SRS in keeping with the 
clinical presentation and the negative clinical score (2/6 items).
Lastly, in patient 28, who presents five NH-CSS criteria except 
for relative macrocephaly at birth (Table 3), we identified a deletion 
on chromosome 17q, arr[GRCh37] 17q22(57075470_57235248)
x1 mat, of 159.8 kb, involving the TRIM37, SKA2, and PRR11 
genes (Table 2, Figure 1E). Mutations in the tripartite motif 
containing 37 (TRIM37) gene (OMIM*605073) are causative of 
the MULIBREY nanism (OMIM#253250), a recessive syndrome 
with SRS overlapping clinical features (Hämäläinen et al., 2006). 
Indeed, TRIM37 gene sequencing revealed a pathogenic single 
base change c.1949-12 A > G in intron 18 (NM_001005207) 
inherited from the patient’s healthy father (Figure 1E), as 
reported by Mozzillo et al. (2016).
Potentially Pathogenic Variants (PP-CNV)
Two CNVs were classified as PP variants on the basis of gene 
content and genomic position criteria. Figure 3 shows the 
genomic regions containing the PP-CNVs of patients 8 and 18, 
as well as the integrated molecular analyses performed to assess 
their pathogenic effect.
Specifically, in patient 8, the aCGH analysis showed a duplication 
of 445 kb in 19q, arr[GRCh37] 19q13.42(54039784_54484439)
x3 mat (Table 2, Figure 3A-1). The patient’s clinical data 
were insufficient for NH-CSS evaluation. She showed facial 
dymorphisms reminiscent of SRS and growth retardation during 
early childhood (Table 3). The proximal duplication breakpoint 
(bkp) lies within the zinc finger protein 331 (ZNF331) gene 
(OMIM*606043) (isoform NM_018555), an imprinted gene yet 
unrelated to SRS. qPCR experiments clarified that the ZNF331 
gene and its two maternally methylated DMRs (ZNF331:alt-TSS-
DMR1 and ZNF331:alt-TSS-DMR2) are fully duplicated (Figure 
3A-2), and consistently, pyrosequencing analysis of DMR2 
showed an increase of methylation in the patient and her mother 
as compared with controls (Figure 3A-3).
In patient 18, a duplication of 975 kb at 7p, arr[GRCh37] 
7p12.1(50981149_51956510)x3 mat (Table 2, Figure 3B-1), 
was detected. The patient fulfills the NH-CSS criteria with a 
score of 4/5. No information about her head circumference at 
birth was available to establish a proper clinical SRS diagnosis. 
She did not show severe birth retardation, but psychomotor 
developmental delay and her facial dysmorphisms were not 
associated with SRS (Table 3). Her mother did not show any SRS 
features. The duplication fully involves the cordon-bleu (COBL) 
gene (OMIM*610317) and interestingly, its distal bkp maps 
130 kb from the promoter of the growth factor receptor-bound 
protein 10 (GRB10) gene (OMIM*601523), which is a candidate 
for SRS (Wakeling et al., 2017; Miyoshi et al., 1998). Further 
molecular analyses revealed that the duplication is transmitted 
by the phenotypically healthy grandfather (Figure 3B-2). Neither 
GRB10 expression nor GRB10:alt-TSS-DMR methylation are 
impaired by the structural variant in the carrier family members 
(Figures 3B-3–5), with the exception of a slight hypomethylation 
detected in the mother compared with her daughter and controls 
(Figures 3B-4 and 5).
DISCUSSION
This study aimed to evaluate, through high-resolution aCGH, 
a cohort of 34 patients with clinical signs resembling SRS but 
negative to (epi)genetic tests. Five individuals, accounting for 
15% of the starting cohort, were found to harbor pathogenic 
CNVs (P-CNVs), attesting a frequency higher than that shown 
by similar studies, ranging from 6% (Inoue et al., 2017) or 7% 
(Azzi et al., 2015) to 12% (Sachwitz et al., 2017). Furthermore, our 
detection rate increases to 21% by including two cases carrying 
PP-CNVs, whose exact pathogenic role awaits confirmation by 
further studies.
Regarding the NH-CSS, three out of five patients with 
P-CNVs (patients 17, 20, and 28) and one (patient 18) out of two 
with PP-CNVs fulfill the criteria, and one patient (patient 7) with 
P-CNV scored positive for three clinical items, reinforcing the 
recommendation to process by aCGH patients with a clinical 
suspicion of SRS. Only one patient (patient 17) can be diagnosed 
clinical SRS, while the other six patients, despite matching four 
or more criteria, are unlikely SRS.
Our results confirm the genetic heterogeneity found in 
similar studies (Tumer et al., 2018), increasing the number of 
structural variants identified to date in patients with SRS or 
similar features. The detected CNVs involve distinct genomic 
regions either previously associated with growth delay conditions 
(1q24.3-q25.3, 17p13.3, 17q22, and 22q11.2-q11.22) and with 
SRS spectrum (7p12.1 and 7p15.3-p14.3) or outlined for the first 
time (19q13.42), hence enhancing the definition of reported and 
novel SRS overlapping syndromes.
Patient 7 carries a P-CNV associated with 1q24q25 
microdeletion syndrome (Figure 1A) and his phenotype, 
matching that of the described patients (Burkardt et al., 2011; 
Ashraf et al., 2015), recapitulates the SRS phenotype in terms 
of a few minor dysmorphisms and growth retardation. Three 
“key” genes for growth delay map within the deletion: CENPL, 
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centromere protein L (OMIM*611503), involved in kinetochore 
function and mitotic progression (Burkardt et al., 2011); PAPPA2, 
pappalysin 2, encoding a protease for IGFBP3 and IGFBP5 
involved in IGF-1 availability (Dauber et al., 2016), whose 
biallelic mutations account for short stature (Dauber et al., 2016); 
and LHX4, LIM homeobox 4 (OMIM*602146) causative of the 
dominant pituitary hormone deficiency-4 syndrome (CPHD4; 
OMIM*262700).
The duplication at 17p13.3 of the clinically SRS patient 17 
includes only five genes and to the best of our knowledge is the 
smallest reported to date. Two non-overlapping deletions of the 
same region have been identified in clinically suspected SRS patients 
(Spengler et al., 2012). Microduplications at 17p13.3, involving the 
YWHAE and CRK genes, similarly to our patient, are associated with 
macrosomia in the majority of cases (Henry et al., 2016). Conversely, 
patient 17 displays growth retardation and does not show the 
FIGURE 3 | Physical map of the genomic regions and molecular characterization of the potentially pathogenic CNVs identified by array CGH. The 19q13.42 (A-1) and 
7p12.1 (B-1) regions showing in blue the duplication identified in patients 8 (A-1) and 18 (B-1). The RefSeq genes are depicted in dark blue, and the OMIM disease 
genes in green; the candidate genes are illustrated by red boxes, and the differentially methylated regions (DMRs) in black. The positions of pyrosequencing assays 
and qPCR probes used in the CNVs’ molecular characterization are reported in black and blue, respectively. The images are a modification of a version obtained from 
the UCSC Genome Browser (human genome assembly GRCh37/hg19). (A-2) Copy number analysis by using qPCR probes specific for ZNF331 gene promoter 
confirmed the entire duplication of ZNF331 gene in both patient 8 and her mother (M). (A-3) Pyrosequencing analysis performed on blood DNA of the ZNF331:alt-
TSS-DMR2 showed an hypermethylation level in both patient 8 and her mother (M) compared with healthy controls. (B-2) Patient 18’s family tree showing duplication 
transmission. (B-3) Relative expression of GRB10 blood mRNA in patient 18 and her mother (M), compared with healthy controls. Data were normalized against 
GAPDH as housekeeping gene; similar results were obtained using TBP, HMBS, and RPLP0 as normalizer (data not shown). (B-4, B-5) Pyrosequencing analysis 
of the GRB10:alt-TSS-DMR performed on blood DNA showed a methylation level in patient 18 and her maternal grandfather (MGF) compared with healthy controls 
with both assays, while in patient 18’s mother (M), a hypomethylation level was detected with both assays. CNVs, copy number variants; CGH, comparative genomic 
hybridization; OMIM, Online Mendelian Inheritance in Man; qPCR, quantitative polymerase chain reaction; UCSC, University of California Santa Cruz.
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microduplication-associated neurologic dysfunctions, confirming 
the incomplete penetrance and highly variable expressivity of this 
duplication syndrome. Among the duplicated genes playing a role in 
cellular growth pathways, CRK (OMIM*164762) has been proposed 
as a candidate for body size determination (Østergaard et al., 2012).
Patient 23 was found to carry the distal 22q11.2 microdeletion 
syndrome (OMIM#611867), a recurrent rearrangement 
associated with prenatal and postnatal growth retardation (Ben-
Shachar et al., 2008). She is unlikely SRS, though the same 1.1 
Mb deletion has been reported in an SRS patient matching five 
NH-CSS criteria (Bruce et al., 2010), and an atypical distal 22q11.2 
microdeletion has been described in a patient with clinical features 
reminiscent of SRS (Garavelli et al., 2011). The main candidate 
genes of this syndrome are UBE2L3, ubiquitin conjugating 
enzyme E2 L3 (OMIM*603721), whose homozygous mutations in 
mice lead to placental defects and growth retardation (Harbers 
et al., 1996), and MAPK1, mitogen-activated protein kinase 1 
(OMIM*176948), encoding a protein kinase with an essential role 
in embryonic development (Saba-El-Leil et al., 2003).
Patient 28 was diagnosed to be affected by MULIBREY 
nanism (OMIM#253250), as he carries a 17q22 chromosome 
deletion and a concomitant TRIM37 splicing mutation affecting 
the non-deleted chromosome, as already described (Mozzillo 
et al., 2016), reconfirming the clinical overlap between SRS and 
MULIBREY nanism (Hämäläinen et al., 2006; Jobic et al., 2017).
Finally, patient 20 showed a de novo deletion of 7.5 Mb on the 
paternal chromosome 7 at p15.3-14.3, proximal to the candidate 
7p12 SRS region. She fulfills the NH-CSS except for body asymmetry, 
less common in upd(7)mat than in 11p15 LOM molecularly 
confirmed SRS patients (Wakeling et al., 2017), and relative 
macrocephaly at birth, although displayed in early childhood. Out 
of the numerous deleted genes that may account for SRS similar 
features, IGF2BP3 is the most relevant, as it encodes for an RNA-
binding factor specific to the 5′UTR of IGF2 mRNA, regulating the 
IGF2 transcript levels during fetal growth and development (Monk 
et al., 2002). A similar IGF2BP3 deletion was found in an SRS patient 
with classical SRS phenotype, supporting the relevance of this locus 
in SRS etiology (Lin et al., 2010). Another interesting disease gene 
is HOXA13, homeobox A13 (OMIM*142959), causative of the 
hand-foot-genital syndrome (HFGS, OMIM#140000), which is 
characterized by small feet with unusually short and big toes and 
abnormal thumbs, and urogenital malformations. This gene is also 
involved in heterogeneous chromosomal aberrations of the 7p15-
p14 region, and like the reported cases, our patient shows feet and 
kidney anomalies (Devriendt et al., 1999; Dunø et al., 2004; Kosaki 
et al., 2005; Fryssira et al., 2011; Jun et al., 2011; Hosoki et al., 2012; 
Pezzani et al., 2015).
Regarding PP-CNVs, the maternal duplication at 19q13.42, 
identified in patient 8, comprises the chromosome 19 microRNA 
cluster (C19MC) and the ZNF331 gene, whose ZNF331:alt-TSS-
DMR2 was found to be hypermethylated in both patient and mother. 
ZNF331, encoding a zinc finger protein that acts as a tumor suppressor 
and negative regulator of cellular growth (Yu et al., 2013; Wang et al., 
2013), was found to be differentially expressed between normal and 
IUGR placentas (Diplas et al., 2009). Up to now, data on maternal or 
paternal ZNF331 expression are scarce and contradictory (Lambertini 
et al., 2012; Daelemans et al., 2010; Pollard et al., 2008; Pant et al, 
2006), while the adjacent cluster of 46 miRNAs is paternally 
expressed in the placenta (Noguer-Dance et al., 2010). Recently, a 
paternally inherited duplication of 1.06 Mb, fully involving ZNF331 
and C19MC, was stated to be pathogenic in a fetus with IUGR (Petre 
et al., 2018) that in our opinion might be ascribed to the duplication 
of the paternally expressed C19MC cluster. The fetus’s father, in turn, 
inherited the duplication from his mother mirroring, our patient 
8 and her mother, but his phenotype is not described. ZNF331 is 
worth considering as a candidate gene for growth disorders, though 
further studies are needed to elucidate the pathomechanism.
A second maternal duplication at 7p12 was identified and 
categorized as PP-CNV in case 18 presenting a positive clinical 
score of 4 out of 5 (relative macrocephaly at birth is unknown). 
The CNV maps about 130 kb from the promoter of GRB10 (Figure 
3B-1), an imprinted gene with biallelic expression in many tissues, 
but with maternal expression in muscle and placenta (Blagitko et al., 
2000; Monk et al., 2009). Genomic imbalances affecting GRB10, in 
particular, maternal duplications involving GRB10, lead to SRS-
like features and growth retardation (Tumer et al., 2018; Yuan et al., 
2016). Since the duplication is inherited from the healthy maternal 
grandfather via the healthy mother, an imprinting transmission 
pattern might be envisaged. Even if concordant results from both 
expression and methylation analyses on family member blood 
cells did not support this hypothesis, the pathogenic role of the 
duplication remains challenging as a perturbed gene regulation 
cannot be ruled out during the fetal development, in particular in 
tissues where the gene is only maternally expressed.
In conclusion, we found five clinically relevant CNVs and two 
VOUS—PP-CNVs in distinct chromosomal regions in 15% and 
6% of clinically suspected SRS patients, respectively. Out of these 
variants, two, harbored by patients matching the NH-CSS criteria, 
map to 7p distinct regions, reinforcing the contribution of the short 
arm of chromosome 7 to SRS-like etiology. Further investigations on 
a larger cohort of SRS/SRS-like patients are needed, firstly, to confirm 
the observed relevant CNVs detection rate, to exclude coincidental 
findings unrelated to the phenotype of the reported patients, and to 
support the role of the appointed genes in SRS and similar conditions.
Genome-wide aCGH scan integrated by in-depth studies 
is re-confirmed as an appropriate and powerful tool for 
achieving a differential diagnosis in both clinically and unlikely 
SRS diagnosed patients and to highlight novel chromosome 
alterations and genomic regions associated with SRS and similar 
growth retardation disorders.
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